AAPL344.59+5.09 (+1.50%) ▲|ABBV283.11-5.97 (-2.07%) ▼|ABT98.83-3.63 (-3.54%) ▼|ACN240.08+0.96 (+0.40%) ▲|ADBE255.87-0.86 (-0.34%) ▼|AMAT411.29+6.31 (+1.56%) ▲|AMD550.08+15.34 (+2.87%) ▲|AMGN435.60-3.34 (-0.76%) ▼|AMT179.03-4.53 (-2.47%) ▼|AMZN262.64+0.01 (+0.00%) ▲|AVGO337.09+2.72 (+0.81%) ▲|AXP323.91+5.57 (+1.75%) ▲|BA191.62+1.15 (+0.60%) ▲|BAC51.01+0.37 (+0.72%) ▲|BKNG157.98-5.94 (-3.62%) ▼|BLK1,136.54+7.86 (+0.70%) ▲|BMY60.84-0.85 (-1.37%) ▼|BNY146.34+2.09 (+1.45%) ▲|BRK-B542.91+3.09 (+0.57%) ▲|C123.25+0.74 (+0.60%) ▲|CAT736.22+10.98 (+1.51%) ▲|CL93.68-0.86 (-0.91%) ▼|CMCSA21.87-0.50 (-2.21%) ▼|COF209.61+8.05 (+3.99%) ▲|COP145.84-0.12 (-0.08%) ▼|COST995.37+0.76 (+0.08%) ▲|CRM242.91+0.48 (+0.20%) ▲|CSCO106.85+0.14 (+0.13%) ▲|CVS94.29-0.46 (-0.49%) ▼|CVX226.33+0.62 (+0.27%) ▲|DE631.14-1.07 (-0.17%) ▼|DHR232.70+8.46 (+3.77%) ▲|DIS110.84-0.83 (-0.74%) ▼|DUK121.43+0.10 (+0.08%) ▲|EMR163.27+2.81 (+1.75%) ▲|FDX298.99+0.23 (+0.08%) ▲|GD346.42+1.98 (+0.57%) ▲|GE300.83+0.96 (+0.32%) ▲|GEV928.69+38.36 (+4.31%) ▲|GILD152.93-3.59 (-2.29%) ▼|GM75.75-1.34 (-1.74%) ▼|GOOG328.98-7.42 (-2.21%) ▼|GOOGL332.99-7.29 (-2.14%) ▼|GS899.26+14.45 (+1.63%) ▲|HD314.35-0.76 (-0.24%) ▼|HON213.59+0.27 (+0.13%) ▲|IBM244.06+2.14 (+0.88%) ▲|INTC92.55+0.86 (+0.93%) ▲|INTU334.65-0.64 (-0.19%) ▼|ISRG431.71-6.30 (-1.44%) ▼|JNJ255.95-3.42 (-1.32%) ▼|JPM333.71-1.55 (-0.46%) ▼|KO92.91-0.58 (-0.62%) ▼|LIN499.54-2.35 (-0.47%) ▼|LLY1,268.01-15.65 (-1.22%) ▼|LMT549.58+0.87 (+0.16%) ▲|LOW196.58-0.71 (-0.36%) ▼|LRCX266.80+3.35 (+1.27%) ▲|MA623.27+2.85 (+0.46%) ▲|MCD245.81-0.71 (-0.29%) ▼|MDLZ62.81-1.18 (-1.84%) ▼|MDT93.51-1.13 (-1.19%) ▼|META710.75+16.50 (+2.38%) ▲|MMM171.12-0.25 (-0.15%) ▼|MO73.94-0.70 (-0.94%) ▼|MRK148.69+0.39 (+0.26%) ▲|MS183.57+3.17 (+1.76%) ▲|MSFT531.69-0.18 (-0.03%) ▼|MU912.63+16.56 (+1.85%) ▲|NEE78.59-0.27 (-0.35%) ▼|NFLX65.26-3.43 (-4.99%) ▼|NKE37.49-0.39 (-1.03%) ▼|NOW153.29+3.75 (+2.51%) ▲|NVDA220.46+3.99 (+1.84%) ▲|ORCL130.08-1.06 (-0.81%) ▼|PEP135.12+1.10 (+0.82%) ▲|PFE29.77-0.34 (-1.13%) ▼|PG157.75-1.58 (-0.99%) ▼|PLTR199.53+6.93 (+3.60%) ▲|PM196.75-3.15 (-1.58%) ▼|QCOM178.26+2.55 (+1.45%) ▲|RTX191.12-2.22 (-1.15%) ▼|SBUX98.82-0.55 (-0.55%) ▼|SCHW91.92+1.03 (+1.13%) ▲|SO90.71+0.00 (+0.00%) ▲|SPG206.31-0.68 (-0.33%) ▼|T21.98-1.45 (-6.17%) ▼|TMO702.36+14.99 (+2.18%) ▲|TMUS153.32-4.44 (-2.81%) ▼|TSLA386.40+12.69 (+3.40%) ▲|TXN286.26+8.48 (+3.05%) ▲|UBER68.18-0.76 (-1.10%) ▼|UNH416.31-2.96 (-0.70%) ▼|UNP289.75+2.14 (+0.74%) ▲|UPS99.61+1.09 (+1.10%) ▲|USB59.31+0.22 (+0.36%) ▲|V409.27+2.70 (+0.66%) ▲|VZ43.41-1.14 (-2.55%) ▼|WFC82.43+0.23 (+0.28%) ▲|WMT118.01+0.16 (+0.13%) ▲|XOM177.68-0.18 (-0.10%) ▼|AAPL344.59+5.09 (+1.50%) ▲|ABBV283.11-5.97 (-2.07%) ▼|ABT98.83-3.63 (-3.54%) ▼|ACN240.08+0.96 (+0.40%) ▲|ADBE255.87-0.86 (-0.34%) ▼|AMAT411.29+6.31 (+1.56%) ▲|AMD550.08+15.34 (+2.87%) ▲|AMGN435.60-3.34 (-0.76%) ▼|AMT179.03-4.53 (-2.47%) ▼|AMZN262.64+0.01 (+0.00%) ▲|AVGO337.09+2.72 (+0.81%) ▲|AXP323.91+5.57 (+1.75%) ▲|BA191.62+1.15 (+0.60%) ▲|BAC51.01+0.37 (+0.72%) ▲|BKNG157.98-5.94 (-3.62%) ▼|BLK1,136.54+7.86 (+0.70%) ▲|BMY60.84-0.85 (-1.37%) ▼|BNY146.34+2.09 (+1.45%) ▲|BRK-B542.91+3.09 (+0.57%) ▲|C123.25+0.74 (+0.60%) ▲|CAT736.22+10.98 (+1.51%) ▲|CL93.68-0.86 (-0.91%) ▼|CMCSA21.87-0.50 (-2.21%) ▼|COF209.61+8.05 (+3.99%) ▲|COP145.84-0.12 (-0.08%) ▼|COST995.37+0.76 (+0.08%) ▲|CRM242.91+0.48 (+0.20%) ▲|CSCO106.85+0.14 (+0.13%) ▲|CVS94.29-0.46 (-0.49%) ▼|CVX226.33+0.62 (+0.27%) ▲|DE631.14-1.07 (-0.17%) ▼|DHR232.70+8.46 (+3.77%) ▲|DIS110.84-0.83 (-0.74%) ▼|DUK121.43+0.10 (+0.08%) ▲|EMR163.27+2.81 (+1.75%) ▲|FDX298.99+0.23 (+0.08%) ▲|GD346.42+1.98 (+0.57%) ▲|GE300.83+0.96 (+0.32%) ▲|GEV928.69+38.36 (+4.31%) ▲|GILD152.93-3.59 (-2.29%) ▼|GM75.75-1.34 (-1.74%) ▼|GOOG328.98-7.42 (-2.21%) ▼|GOOGL332.99-7.29 (-2.14%) ▼|GS899.26+14.45 (+1.63%) ▲|HD314.35-0.76 (-0.24%) ▼|HON213.59+0.27 (+0.13%) ▲|IBM244.06+2.14 (+0.88%) ▲|INTC92.55+0.86 (+0.93%) ▲|INTU334.65-0.64 (-0.19%) ▼|ISRG431.71-6.30 (-1.44%) ▼|JNJ255.95-3.42 (-1.32%) ▼|JPM333.71-1.55 (-0.46%) ▼|KO92.91-0.58 (-0.62%) ▼|LIN499.54-2.35 (-0.47%) ▼|LLY1,268.01-15.65 (-1.22%) ▼|LMT549.58+0.87 (+0.16%) ▲|LOW196.58-0.71 (-0.36%) ▼|LRCX266.80+3.35 (+1.27%) ▲|MA623.27+2.85 (+0.46%) ▲|MCD245.81-0.71 (-0.29%) ▼|MDLZ62.81-1.18 (-1.84%) ▼|MDT93.51-1.13 (-1.19%) ▼|META710.75+16.50 (+2.38%) ▲|MMM171.12-0.25 (-0.15%) ▼|MO73.94-0.70 (-0.94%) ▼|MRK148.69+0.39 (+0.26%) ▲|MS183.57+3.17 (+1.76%) ▲|MSFT531.69-0.18 (-0.03%) ▼|MU912.63+16.56 (+1.85%) ▲|NEE78.59-0.27 (-0.35%) ▼|NFLX65.26-3.43 (-4.99%) ▼|NKE37.49-0.39 (-1.03%) ▼|NOW153.29+3.75 (+2.51%) ▲|NVDA220.46+3.99 (+1.84%) ▲|ORCL130.08-1.06 (-0.81%) ▼|PEP135.12+1.10 (+0.82%) ▲|PFE29.77-0.34 (-1.13%) ▼|PG157.75-1.58 (-0.99%) ▼|PLTR199.53+6.93 (+3.60%) ▲|PM196.75-3.15 (-1.58%) ▼|QCOM178.26+2.55 (+1.45%) ▲|RTX191.12-2.22 (-1.15%) ▼|SBUX98.82-0.55 (-0.55%) ▼|SCHW91.92+1.03 (+1.13%) ▲|SO90.71+0.00 (+0.00%) ▲|SPG206.31-0.68 (-0.33%) ▼|T21.98-1.45 (-6.17%) ▼|TMO702.36+14.99 (+2.18%) ▲|TMUS153.32-4.44 (-2.81%) ▼|TSLA386.40+12.69 (+3.40%) ▲|TXN286.26+8.48 (+3.05%) ▲|UBER68.18-0.76 (-1.10%) ▼|UNH416.31-2.96 (-0.70%) ▼|UNP289.75+2.14 (+0.74%) ▲|UPS99.61+1.09 (+1.10%) ▲|USB59.31+0.22 (+0.36%) ▲|V409.27+2.70 (+0.66%) ▲|VZ43.41-1.14 (-2.55%) ▼|WFC82.43+0.23 (+0.28%) ▲|WMT118.01+0.16 (+0.13%) ▲|XOM177.68-0.18 (-0.10%) ▼|
14.6 C
New York
Wednesday, October 21, 2026

Tag: therapeutics

newsFORsourcecompanycontentinformation1releasesmarket

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy...

CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom.

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for...

Media Release

COPENHAGEN, Denmark; June 15, 2025

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

Basel, 15 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new dosing restrictions, effective immediately, for ELEVIDYS™ (delandistrogene moxeparvovec), for non-ambulatory Duchenne muscular dystrophy (DMD) patients, irrespective of age, in both clinical and commercial settings. In the commercial setting, non-ambulatory patients should no longer receive Elevidys. In the clinical trial setting, enrolment and dosing of non-ambulatory patients will be immediately paused until additional risk mitigation measures (e.g. immune modulatory treatment) are implemented in the study protocol. Health authorities, investigators and physicians are being informed so that patient care can be quickly adjusted.

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company’s Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by swelling of the deeper dermal layers of the skin and mucous membranes, is a painful, debilitating symptom of CSU that has significant impact on quality of life. It commonly affects the face (lips and eyelids), hands, feet, and genitalia but can also involve the tongue, uvula, soft palate, and pharynx1.

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response

GT Biopharma Appoints New Member to its Board of Directors

SAN FRANCISCO, CALIFORNIA, June 13, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced the appointment of David C. Mun-Gavin to its Board of Directors.

RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split

SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that a 1-for-8 reverse stock split of its outstanding shares of common stock will be effective at 11:59 pm Eastern Time June 16, 2025.

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTherapeutics

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers